Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/ncomms15840 http://scihub22266oqcxt.onion/10.1038/ncomms15840 C5501969!5501969 !28643774     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28643774 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Nat+Commun 2017 ; 8 (ä): 15840 Nephropedia Template TP {{tp|p=28643774 |t=2017. Insufficient antibody validation challenges oestrogen receptor beta research |pdf=|usr=}}{{28643774 }} gab.com Text Insufficient antibody validation challenges oestrogen receptor beta research JO: Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=28643774 #FOAvip The discovery of oestrogen receptor ? (ER?/ESR2) was a landmark discovery. Its reported expression and homology with breast cancer pharmacological target ER? (ESR1) raised hopes for improved endocrine therapies. After 20 years of intense research, this has not materialized. We here perform a rigorous validation of 13 anti-ER? antibodies, using well-characterized controls and a panel of validation methods. We conclude that only one antibody, the rarely used monoclonal PPZ0506, specifically targets ER? in immunohistochemistry. Applying this antibody for protein expression profiling in 44 normal and 21 malignant human tissues, we detect ER? protein in testis, ovary, lymphoid cells, granulosa cell tumours, and a subset of malignant melanoma and thyroid cancers. We do not find evidence of expression in normal or cancerous human breast. This expression pattern aligns well with RNA-seq data, but contradicts a multitude of studies. Our study highlights how inadequately validated antibodies can lead an exciting field astray. Twit Text FOAVip Insufficient antibody validation challenges oestrogen receptor beta research ????Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=28643774 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28643774 #FOAvip English Wikipedia <ref>{{Cite pmid|28643774 }}</ref> Insufficient antibody validation challenges oestrogen receptor beta research #MMPMID28643774 Andersson S ; Sundberg M ; Pristovsek N ; Ibrahim A ; Jonsson P ; Katona B ; Clausson CM ; Zieba A ; Ramström M ; Söderberg O ; Williams C ; Asplund A Nat Commun 2017[Jun]; 8 (ä): 15840 PMID28643774 show ga The discovery of oestrogen receptor ? (ER?/ESR2) was a landmark discovery. Its reported expression and homology with breast cancer pharmacological target ER? (ESR1) raised hopes for improved endocrine therapies. After 20 years of intense research, this has not materialized. We here perform a rigorous validation of 13 anti-ER? antibodies, using well-characterized controls and a panel of validation methods. We conclude that only one antibody, the rarely used monoclonal PPZ0506, specifically targets ER? in immunohistochemistry. Applying this antibody for protein expression profiling in 44 normal and 21 malignant human tissues, we detect ER? protein in testis, ovary, lymphoid cells, granulosa cell tumours, and a subset of malignant melanoma and thyroid cancers. We do not find evidence of expression in normal or cancerous human breast. This expression pattern aligns well with RNA-seq data, but contradicts a multitude of studies. Our study highlights how inadequately validated antibodies can lead an exciting field astray. |Antibodies/*analysis [MESH] |Breast Neoplasms/genetics/metabolism [MESH] |Cell Line [MESH] |Estrogen Receptor beta/*analysis/genetics/metabolism [MESH] |Female [MESH] |Humans [MESH] |Immunohistochemistry [MESH] |Lymphocytes/chemistry/metabolism [MESH] |Male [MESH] |Ovary/chemistry/metabolism [MESH]Insufficient antibody validation challenges oestrogen receptor beta re(epmc).pdf DeepDyve Pubget Overpricing